Abstract 1741P
Background
Little research has been made on real-world clinical scenarios of potential ethical relevance in specific cancers, including sarcomas.
Methods
Our sarcoma multidisciplinary tumor board (MTB) discusses all cases of adult patients with soft tissue sarcomas, bone sarcomas and GIST selected by the clinical oncologist in charge as deserving a multidisciplinary discussion. Over a 1-yr interval, all discussed cases were filtered by a group of senior and junior experts in bioethics and sarcomas in order to highlight those of potential ethical concern, i.e. whenever a problematic conflict could be envisaged between the ethical principles of beneficence, non-maleficence, autonomy and justice. These cases were retrospectively reviewed, and an attempt was made to group them into distinct ethical scenarios.
Results
From January to December 2023, 327 sarcoma cases were discussed by our MTB. Forty-one cases (12%) were prospectively or retrospectively selected as carrying possible ethical relevance. Among them, the following clinical scenarios were identified (total >100% since scenarios are not mutually exclusive): 1. ethically-relevant uncertainty about a diagnostic/treatment option (46%); 2. best treatment option at a high-risk of complications of problematic acceptance (5%); 3. controversial futility (17%); 4. problematic trade-off between quality and quantity of life (17%); 5. problematic management of patient dissent (15%); 6. clinical disagreement of potential ethical concern (10%); 7. problematic communication of all clinical implications to the individual patient (15%). 8. controversial enrolment of an eligible patient in a clinical trial or trial requirements of ethical concern in the individual patient (2%); 9. best clinical option conflicting with social/economical constraints (0.3%); 10. bedside rationing, or perception of implicit rationing of scarce resources (2%).
Conclusions
A non-negligible incidence of ethically-relevant clinical cases was observed. Sarcoma centres should be aware of specific ethical implications possibly affecting their everyday practice. Paradigmatic clinical cases for each of the ten clinical scenarios proposed herein will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1763P - Initial tumour size and residual mitotic count post-neoadjuvant imatinib linked to shorter relapse-free survival in GIST patients
Presenter: Javier Pozas Perez
Session: Poster session 06
1764P - Role of PIK3CA as a predictive biomarker in metastatic, imatinib-resistant GIST: A ct-DNA substudy of the VOYAGER trial
Presenter: Lennart Schardt
Session: Poster session 06
1765P - Second-line targeted therapy patterns and outcomes of advanced gastrointestinal stromal tumor: A prospective, multicentered real-world study
Presenter: Xinhua Zhang
Session: Poster session 06
1766P - Updated results of the RINGSIDE phase II trial and open-label extension of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 06
1767P - Pegylated liposomal doxorubicin in symptomatic desmoid tumor
Presenter: Kjetil Boye
Session: Poster session 06
1768P - Desmoid tumors: Experience of a Spanish reference center
Presenter: Ana Gutierrez Ortiz
Session: Poster session 06
1769P - Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior anti–colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
Presenter: Cesar Serrano
Session: Poster session 06
1771P - Blessed: Expanded yccess for DeltaRex-G in vivo gene therapy for sarcoma, pancreas and breast cancer (NCT04091295) and other solid malignancies (IND# 19130)
Presenter: Sant Chawla
Session: Poster session 06
1772P - Phosphoproteomic biomarker for afatinib response stratification in advanced chordoma
Presenter: Christoph Stange
Session: Poster session 06